Home › Funds › JOHNSON & JOHNSON › ACET
JOHNSON & JOHNSON position in ACET
ADICET BIO INC · Health Care
JOHNSON & JOHNSON reported holding 22,779 shares of ACET (ADICET BIO INC) in its Q3 2026 13F filing — a position valued at US$163K, representing 0.02% of its reported portfolio and ranking #15 among its reported holdings. JOHNSON & JOHNSON has disclosed ACET holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How JOHNSON & JOHNSON's ACET position evolved
JOHNSON & JOHNSON first disclosed a stake in ACET in Q3 2023 at 728,944 shares (US$999K). The position peaked in Q4 2023 at 688,595 shares, worth US$1.3M. Across 13 filings, JOHNSON & JOHNSON increased the stake 0 time(s), trimmed it 3 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 22,779 shares valued at US$163K. Notable position changes include a 47% trim in Q1 2024 (shares fell 49% over the following quarter), a 94% trim in Q4 2025 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 728.94K | $998.65K | New |
| Q4 2023 | 688.60K | $1.30M | Reduce |
| Q1 2024 | 364.47K | $856.51K | Reduce |
| Q2 2024 | 364.47K | $441.01K | Hold |
| Q3 2024 | 364.47K | $524.84K | Hold |
| Q4 2024 | 364.47K | $350.62K | Hold |
| Q1 2025 | 364.47K | $275.18K | Hold |
| Q2 2025 | 364.47K | $228.01K | Hold |
| Q3 2025 | 364.47K | $295.30K | Hold |
| Q4 2025 | 22.78K | $191.80K | Reduce |
| Q1 2026 | 22.78K | $155.12K | Hold |
| Q2 2026 | 22.78K | $196.81K | Hold |
| Q3 2026 | 22.78K | $162.64K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ACET and 13F data
ACET (ADICET BIO INC) is a Health Care company. 25 other funds we track also report a position in ACET — the largest reported positions include Stonepine Capital Management, LLC (US$2.1M), Carlyle Group Inc. (US$1.3M), REGENERON PHARMACEUTICALS, INC. (US$432K). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ACET
- Stonepine Capital Management, LLC 245.52K sh · $2.12M · Q2 2026
- Carlyle Group Inc. 184.29K sh · $1.32M · Q3 2026
- REGENERON PHARMACEUTICALS, INC. 60.51K sh · $432.05K · Q3 2026
More on JOHNSON & JOHNSON
FAQ
How long has JOHNSON & JOHNSON held ACET?
JOHNSON & JOHNSON has disclosed ACET holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is JOHNSON & JOHNSON's current position in ACET?
As of Q3 2026, JOHNSON & JOHNSON holds 22.78K shares of ACET (ADICET BIO INC), valued at $162.64K, representing 0.02% of its reported portfolio and ranking #15.
Has JOHNSON & JOHNSON been buying or selling ACET?
In the latest 13F filing (Q3 2026), JOHNSON & JOHNSON held unchanged its position in ACET. The position peaked in Q4 2023 at 688.60K shares.
Which other funds hold ACET?
Other major institutional holders of ACET include Stonepine Capital Management, LLC, Carlyle Group Inc., REGENERON PHARMACEUTICALS, INC., among 25 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.